Page 3 - Pharma Sector

India's pharma, healthcare deals surge 166% to $3.5 bn in Q3: Report

Grant Thornton Bharat says India's pharma and healthcare sectors saw renewed investor confidence, driven by consolidation across pharma, biotech, and hospital segments

Pharma, healthcare sector deals hit $3.5 billion in Sep quarter: Report

Indian pharmaceutical and healthcare sector recorded a total of 72 transactions valued at USD 3.5 billion in the third quarter ended September this year, according to Grant Thornton Bharat's dealtracker. This included three IPOs worth USD 428 million and one QIP worth USD 88 million, Grant Thornton Bharat said in a statement. Excluding public market activity, private deals accounted for USD 3 billion across 68 transactions, marking a sharp rebound in investor appetite, it added. The surge was driven by seven high value deals worth USD 2.6 billion, reflecting renewed investor confidence in scale and consolidation plays across pharma, biotech, and hospital segments, and mirroring the sector's strong fundamentals and growth potential. The standout transaction of the quarter was Torrent Pharma's USD 1.4 billion acquisition of a 46 per cent stake in JB Chemicals & Pharmaceuticals, strengthening its position in high-growth therapeutic segments and chronic care markets, it added. "Q3 ...

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz

Domestic business and exports are expected to be a shot in the arm; hospitals and diagnostics to lag

Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

Cough syrup deaths: SC rejects PIL seeking CBI probe, safety review

The Supreme Court on Friday dismissed a PIL seeking an inquiry and systemic reform in drug safety mechanisms in the wake of deaths of children in Madhya Pradesh and Rajasthan allegedly due to consumption of toxic cough syrups. A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL filed by lawyer Vishal Tiwari after Solicitor General Tushar Mehta objected to it. The top law officer said the petitioner reads the newspaper and rushes to the court. The bench, which was initially of the view that the notice should be issued, later dismissed it. Mehta said he was not appearing for any state at the moment but the seriousness with which states like Tamil Nadu and Madhya Pradesh are taking actions cannot be undermined. Moreover, there are proper law enforcement mechanisms in states, he added. The bench asked Tiwari as to how many PILs he has filed so far in the top court and on being told that he has moved eight to 10 such pleas so far

Pharma stocks rise as US considers exempting generics from tariffs

Among major gainers, Aurobindo Pharma led the rally, surging 4.49 per cent to Rs 1,118.9, followed by Lupin, which climbed 2.73 per cent to Rs 1,957.6

Drug regulator begins pan-Indian inspection of cough syrup makers

The regulator has sought a list of cough syrup manufacturers from all states and UTs following reports of toxic contaminants linked to child deaths in Madhya Pradesh

Mohan Yadav blames Tamil Nadu for poor cooperation in cough syrup case

After 24 child deaths linked to toxic cough syrup, Madhya Pradesh CM Mohan Yadav accuses Tamil Nadu of not cooperating in the investigation into drug safety lapses

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

A deadly dose of neglect: Bitter truth behind cough syrup scare

Bottled negligence: DEG contamination exposes gaps in inspections, leaving pharma units from Gujarat to Kerala under the microscope

Unhealthy practices: Regulatory vigilance on pharma needs a relook

Deaths from ingesting contaminated cough syrups in India have occurred with distressing frequency for decades

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Rubicon Research IPO opens Oct 9; key risks, strengths you must know

Rubicon Research IPO is available at a price band of ₹461-485 per share, with a lot size of 30 shares

Health Secy reviews GMP norms with states after cough syrup deaths

Union Health Secretary Punya Salila Srivastava chaired a meeting with states after 11 children died in MP and Rajasthan, stressing strict GMP compliance and rational use of cough syrups in children

IPA appoints Zydus Lifesciences MD Sharvil Patel as new President

Sharvil Patel takes over as President of IPA from Samir Mehta, with Glenn Saldanha appointed Vice President, as the industry navigates reforms and global challenges

Rubicon Research sets IPO price band at ₹461-475; check key dates, lot size

Rubicon Research IPO will open for subscription on Thursday, October 9, 2025, and close on Monday, October 13, 2025

Trump to launch 'TrumpRx', to make drugs cheaper for Americans, says report

After talks with US President Donald Trump, global pharma giant Pfizer is further expected to announce a $70 billion investment in research, development and domestic manufacturing